{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045338","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.695109+00:00","generated_at":"2026-05-30T00:40:37.550311+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Abeona Q3 net loss $30.3M; FDA sets pz-cel PDUFA Apr 29, 2025","bullets":["Net loss Q3 2024: $30.3M vs $11.8M YoY; includes $15.2M warrant revaluation loss.","Cash, equivalents and investments $110.0M; down $13M from Q2; cash runway into 2026.","FDA accepted pz-cel BLA resubmission; PDUFA target action date April 29, 2025.","CMS granted pz-cel product-specific code and Pre-MDC MS-DRG 018 reimbursement.","New U.S. patent issued for pz-cel (exp. 2037); lease for added manufacturing capacity."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045338","json":"https://secwatch.observer/filing/0001493152-24-045338.json","markdown":"https://secwatch.observer/filing/0001493152-24-045338.md","text":"https://secwatch.observer/filing/0001493152-24-045338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/0001493152-24-045338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:40:37.550311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}